Skye

Ted Tenthoff is a Managing Director and Senior Research Analyst at Piper Sandler, specializing in biotechnology equity research with a particular focus on innovative companies targeting the endocannabinoid system and metabolic disorders. He actively covers public biopharmaceutical companies such as Skye Bioscience, providing investment recommendations and market insights; his recent analysis has contributed to a consensus price target indicating a potential upside of over 500% for covered stocks and has been referenced alongside other major Wall Street firms. Tenthoff began his career as an equity analyst in the early 2000s and has held roles at several leading investment firms before joining Piper Sandler, where he continues to deliver high-impact coverage of key clinical and commercial catalysts. He maintains professional credentials through FINRA registration and relevant securities industry licenses, and his performance track record and rankings are regularly cited in analyst consensus reports.